Risk of thrombosis and infections of central venous catheters and totally implanted access ports in patients treated for cancer

Thrombosis Research

Volumn 125, Issue 4, 2010, Pages 318-321

  Beckers, M M J ^a   Ruven, H J T ^a   Seldenrijk, C A ^a   Prins, M H ^a   Biesma, D H ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Central venous catheter; CVC; Infections; Thrombosis; TIAP; Totally implanted access ports

Indexed keywords

ANTINEOPLASTIC AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CATHETER INFECTION; CENTRAL VENOUS CATHETER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; IMPLANT; MALE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SOLID TUMOR; TOTALLY IMPLANTED ACCESS PORT; VEIN THROMBOSIS;

ANTI-BACTERIAL AGENTS; CATHETERIZATION; CATHETERIZATION, CENTRAL VENOUS; HEMATOLOGIC NEOPLASMS; HUMANS; INCIDENCE; INFECTION; NEOPLASMS; NERVOUS SYSTEM NEOPLASMS; PATIENTS; RISK FACTORS; THROMBOSIS; VEINS; VENOUS THROMBOSIS;

EID: 77949570015     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.06.008     Document Type: Article

References (36)

1. Vandijck D.M., Depaemelaere M., Labeau S.O., Depuydt P.O., Annemans L., Buyle F.M., et al. Daily cost of antimicrobial therapy in patients with Intensive Care Unit-acquired, laboratory-confirmed bloodstream infection. Int J Antimicrob Agents 3 (2008) 161-165
2. Console G., Calabro C., Nardulli P., Digiuseppe F., Rucci A., Russo P., et al. Clinical and economic effects of central venous catheters on oncology patient care. J Chemother 19 (2007) 309-314
3. Blot S.I., Depuydt P., Annemans L., Benoit D., Hoste E., De Waele J.J., et al. Clinical and economic outcomes in critically ill patients with nosocomial catheter-related bloodstream infections. Clin Infect Dis 41 (2005) 1591-1598
4. Rosovsky R.P., and Kuter D.J. Catheter-related thrombosis in cancer patients: pathophysiology, diagnosis, and management. Hematol Oncol Clin North Am 19 (2005) 183-202
5. Verso M., Agnelli G., Kamphuisen P.W., Ageno W., Bazzan M., Lazzaro A., et al. Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients. Intern Emerg Med 3 (2008) 117-122
6. Fijnheer R., Paijmans B., Verdonck L.F., Nieuwenhuis H.K., Roest M., and Dekker A.W. Factor V Leiden in central venous catheter-associated thrombosis. Br J Haematol 118 (2002) 267-270
7. Biffi R., De Braud F., Orsi F., Pozzi S., Arnaldi P., Goldhirsch A., et al. A randomized, prospective trial of central venous ports connected to standard open-ended or Groshong catheters in adult oncology patients. Cancer 92 (2001) 1204-1212
8. Mandalà M., Curigliano G., Bucciarelli P., Ferretti G., Mannucci P.M., Colleoni M., et al. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. Ann Oncol 15 (2004) 590-593
9. Van Rooden C.J., Rosendaal F.R., Meinders A.E., Van Oostayen J.A., Van Der Meer F.J., et al. The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis. Haematologica 89 (2004) 201-206
10. Jansen F.H., van der Straaten H.M., Roest M., Haas F., de Groot P.G., and Fijnheer R. Elevated levels of D-dimer and fragment 1&2 upon central venous catheter insertion and factor V Leiden predict subclavian vein thrombosis. Haematologica 90 (2005) 499-504
11. Abdelkefi A., Ben Romdhane N., Kriaa A., Chelli M., Torjman L., Ladeb S., et al. Prevalence of inherited prothrombotic abnormalities and central venous catheter-related thrombosis in haematopoietic stem cell transplants recipients. Bone Marrow Transplant 36 (2005) 885-889
12. Raad I.I., Luna M., Khalil S.A., Costerton J.W., Lam C., and Bodey G.P. The relationship between the thrombotic and infectious complications of central venous catheters. JAMA 271 (1994) 1014-1016
13. Lordick F., Hentrich M., Decker T., Hennig M., Pohlmann H., Hartenstein R., et al. Ultrasound screening for internal jugular vein thrombosis aids the detection of central venous catheter-related infections in patients with haemato-oncological diseases: a prospective observational study. Br J Haematol 120 (2003) 1073-1078
14. van Rooden C.J., Schippers E.F., Barge R.M., Rosendaal F.R., Guiot H.F., van der Meer F.J., et al. Infectious complications of central venous catheters increase the risk of catheter-related thrombosis in hematology patients: a prospective study. J Clin Oncol 23 (2005) 2655-2660
15. Nouwen J.L., Wielenga J.J., van Overhagen H., Laméris J.S., Kluytmans J.A., Behrendt M.D., et al. Hickman catheter-related infections in neutropenic patients: insertion in the operating theater versus insertion in the radiology suite. J Clin Oncol 17 (1999) 1304
16. Mermel L.A. Prevention of intravascular catheter-related infections. Ann Intern Med 132 (2000) 391-402
17. Randolph A.G., Cook D.J., Gonzales C.A., and Andrew M. Benefit of heparin in central venous and pulmonary artery catheters; a meta-analysis of randomised controlled trials. Chest 113 (1998) 165-171
18. Tesselaar M.E., Ouwerkerk J., Nooy M.A., Rosendaal F.R., and Osanto S. Risk factors for thrombosis in cancer patients. Eur J Cancer 40 (2004) 2253-2259
19. Chaukiyal P., Nautiyal A., Radhakrishnan S., Singh S., and Navaneethan S.D. Thromboprophylaxis in cancer patients with central venous catheters. A systematic review and meta-analysis. Thromb Haemost 99 (2008) 38-43
20. Niers T.M., Di Nisio M., Klerk C.P., Baarslag H.J., Büller H.R., and Biemond B.J. Prevention of catheter-related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled study. J Thromb Haemost 5 (2007) 1878-1882
21. Biffi R., Pozzi S., Agazzi A., Pace U., Floridi A., Cenciarelli S., et al. Use of totally implantable central venous access ports for high-dose chemotherapy and peripheral blood stem cell transplantation: results of a monocentre series of 376 patients. Ann Oncol 15 (2004) 296-300
22. Lemmers N.W., Gels M.E., Sleijfer D.T., Plukker J.T., van der Graaf W.T., de Langen Z.J., et al. Complications of venous access ports in 132 patients with disseminated testicular cancer treated with polychemotherapy. J Clin Oncol 14 (1996) 2916-2922
23. Hartkamp A., van Boxtel A.J., Zonnenberg B.A., and Witteveen P.O. Totally implantable venous access devices: evaluation of complications and a prospective comparative study of two different port systems. Neth J Med 57 (2000) 215-223
24. Koolen D.A., van Laarhoven H.W., Wobbes T., and Punt C.J. Single-centre experience with tunnelled central venous catheters in 150 cancer patients. Neth J Med 60 (2002) 397-401
25. Fischer L., Knebel P., Schröder S., Bruckner T., Diener M.K., Hennes R., et al. Reasons for explantation of totally implantable access ports: a multivariate analysis of 385 consecutive patients. Ann Surg Oncol 15 (2008) 1124-1129
26. Schwarz R.E., Groeger J.S., and Coit D.G. Subcutaneously implanted central venous access devices in cancer patients: a prospective analysis. Cancer 79 (1997) 1635-1640
27. Ng F., Mastoroudes H., Paul E., Davies N., Tibballs J., Hochhauser D., et al. A comparison of Hickman line- and Port-a-Cath-associated complications in patients with solid tumours undergoing chemotherapy. Clin Oncol (R Coll Radiol) 19 (2007) 551-556
28. Lee A.Y., Levine M.N., Butler G., Webb C., Costantini L., Gu C., et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol 24 (2006) 1404-1408
29. Koeleman B.P., Reitsma P.H., Allaart C.F., and Bertina R.M. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 84 (1994) 1031-1035
30. Koeleman B.P., van Rumpt D., Hamulyák K., Reitsma P.H., and Bertina R.M. Factor V Leiden: an additional risk factor for thrombosis in protein S deficient families?. Thromb Haemost 74 (1995) 580-583
31. Bertina R.M., Koeleman B.P., Koster T., Rosendaal F.R., Dirven R.J., de Ronde H., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369 (1994) 64-67
32. Safdar N., Kluger D.M., and Maki D.G. A review of risk factors for catheter-related bloodstream infection caused by percutaneously inserted, noncuffed central venous catheters: implications for preventive strategies. Medicine (Baltimore) 81 (2002) 466-479
33. Garnacho-Montero J., Aldabó-Pallás T., Palomar-Martínez M., Vallés J., Almirante B., Garcés R., et al. Risk factors and prognosis of catheter-related bloodstream infection in critically ill patients: a multicenter study. Intensive Care Med 34 (2008) 2185-2193
34. Johansson E., Björkholm M., Björvell H., Hast R., Takolander R., Olofsson P., et al. Totally implantable subcutaneous port system versus central venous catheter placed before induction chemotherapy in patients with acute leukaemia-a randomized study. Support Care Cancer 12 (2004) 99-105
35. Ratcliffe M., Broadfoot C., Davidson M., and Kelly K.F. Greaves M Thrombosis, markers of thrombotic risk, indwelling central venous catheters and antithrombotic prophylaxis using low-dose warfarin in subjects with malignant disease. Clin Lab Haematol 21 (1999) 353-357
36. Karthaus M. Prophylaxis of catheter-related venous thrombosis in cancer patients. Support Care Cancer 16 (2008) 787-790